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     Aplog-1 is a simplified analog of the tumor-promoting aplysiatoxin with anti-proliferative 22 
and cytotoxic activities against several cancer cell lines.  Our recent findings have suggested 23 
that protein kinase Cδ (PKCδ) could be one of the target proteins of aplog-1.  In the present 24 
study, we synthesized amide-aplog-1 (3), in which the C-1 ester group was replaced with an 25 
amide group, to improve chemical stability in vivo.  Unfortunately, 3 exhibited 70-fold weaker 26 
binding affinity to the C1B domain of PKCδ than that of aplog-1 and negligible 27 
anti-proliferative and cytotoxic activities even at 10-4 M.  A conformational analysis and 28 
density functional theory calculations indicated that the stable conformation of 3 differed from 29 
that of aplog-1.  Since 27-methyl and 27-methoxy derivatives (1, 2) without the ability to bind 30 
to PKC isozymes exhibited marked anti-proliferative and cytotoxic activities at 10-4 M, 3 may 31 
be an inactive control to identify the target proteins of aplogs.   32 
  2 
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 34 
     Aplysiatoxin (ATX) is a potent tumor promoter that has been isolated from the digestive 35 
gland of the sea hare Stylocheilus longicauda.1)  ATX strongly binds to and activates protein 36 
kinase C (PKC) isozymes, as well as 12-O-tetradecanoylpholbol 13-acetate (TPA) and 37 
teleocidin B-4.2,3)  Since PKC is a family of serine/threonine kinases that play pivotal roles in 38 
cellular signal transduction including proliferation, differentiation, and apoptosis,4-6) tumor 39 
promoters may become therapeutic agents for intractable diseases such as cancer, Alzheimer’s 40 
disease (AD), and acquired immune deficiency syndrome (AIDS).  However, difficulties are 41 
associated with their application to therapeutic uses due to their potent tumor-promoting and 42 
inflammatory activities.7,8)  43 
     Bryostatin-1 (bryo-1)9) which was isolated from the marine bryozoan Bugula neritina, is a 44 
unique PKC activator that does not exhibit tumor-promoting or inflammatory activity.  Bryo-1 45 
has been reported to have significant anti-cancer and anti-proliferative activities, and these have 46 
been attributed to activation of the PKCδ,10-12) which plays a tumor suppressor 47 
role and is involved in apoptosis.13-15)  Bryo-1 is also expected to become a therapeutic 48 
candidate for AD16) and AIDS.17)  Despite its potential as a new medicinal lead, further studies 49 
on its mode of action and structural optimization have been hampered due to its limited 50 
availability from natural sources and synthetic complexity.  A functional oriented synthesis of 51 
the simplified analogs of bryo-1 was recently conducted address these issues.18,19)  52 
     As an alternative approach, we developed aplog-1, a simplified analog of ATX.20)  53 
Aplog-1, supplied in only 27 steps via standard reactions, was not tumor-promoting or 54 
inflammatory, but was anti-proliferative even though it has the skeleton of tumor-promoting 55 
ATX.  The anti-proliferative activity of aplog-1 against several cancer cell lines was previously 56 
shown to be similar to that of bryo-1.20)  Furthermore, aplog-1 behaved in a similar manner to 57 
bryo-1 rather than TPA for the translocation of GFP-tagged PKCδ using CHO-K1 cells; aplog-1 58 
as well as bryo-1 translocated GFP-tagged PKCδ to the nuclear membrane and perinuclear 59 
region rather than to the plasma membrane, unlike TPA.20)  To examine the contribution of 60 
PKCδ to the anti-proliferative activity of aplog-1, we recently synthesized 27-methyl and 61 
27-methoxy derivatives (1, 2) that lacked the ability to bind to PKCδ and evaluated their 62 
anti-proliferative activities against 39 human cancer cell lines.21)  Compounds 1 and 2 only 63 
exhibited weak anti-proliferative activities against all the human cancer cell lines tested, 21) 64 
suggesting that the activation of PKCδ was involved in growth inhibitory activities against 65 
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several cancer cell lines that were at least sensitive to aplog-1.   66 
     The next step is to evaluate and improve the anti-proliferative activity of aplog-1 in vivo.  67 
When a bioactive compound is applied to in vivo studies, its chemical stability is critical to the 68 
drug efficacy.  Compounds with ester groups are generally susceptible to hydrolysis by 69 
esterases in vivo.  For example, epothilone B22) showed cytotoxicity by inhibiting the 70 
depolymerization of microtubules23), but its efficacy was limited in vivo due to its ester group.  71 
Ixabepilone is a derivative of epothilone B, in which the ester group is replaced with an amide 72 
group.  Ixabepilone was approved as an anti-breast cancer agent because of its potent 73 
cytotoxicity in vivo.24,25)  Aplog-1 has two ester linkages at C-1 and C-24 in the macrolactone 74 
ring.  We previously reported that benzolactams, the simplified analogs of teleocidins, bound 75 
to PKC isozymes more strongly than their lactone counterparts, benzolactones,26,27) which 76 
prompted us to develop a new derivative of aplog-1 with a more stable amide linkage.  We 77 
herein described the synthesis of amide-aplog-1 (3), in which the ester group at C-1 of aplog-1 78 
was replaced with an amide group, along with several of its biological activities such as PKCδ 79 
binding, in vitro tumor-promoting, anti-proliferative, and cytotoxic activities.  We chose to 80 
replace the C-1 ester group because this site and benzolactones (Figure 1) share a common 81 
hydrophilic substructure, -C(=O)-O-CHR-CH2OH, with an inversed stereochemistry, and the 82 
amide proton of 3 was expected to be at a spatial position similar to that of the hydrogen atom 83 
in the hemiacetal 3-OH group of ATX. 84 
 85 
Results and Discussion 86 
     The synthesis of 3 was accomplished in a convergent approach from a spiroketal (6)20) 87 
and carboxylic acid (5), as shown in Scheme 1.  Compound 4 was prepared from 88 
Z-D-Asp(OtBu)-OH as reported previously28) and the subsequent removal of the t-butyl ester 89 
with trifluoroacetic acid (TFA) afforded the carboxylic acid (5).  The spiroketal 6 was 90 
synthesized from m-hydroxycinnamic acid in a similar manner to the synthesis of aplog-1.20)  91 
Yamaguchi’s esterification29) of 6 with 5 provided 7.  Oxidative cleavage of the olefin group, 92 
followed by esterification with N-hydroxysuccinimide, gave an activated ester.  Immediately 93 
after deprotection of the benzyl (Bn) and carbobenzyloxy (Cbz) groups by catalytic 94 
hydrogenation, lactamization occurred to give 3 in a single step.  The yield (23% in two steps) 95 
was not good because the Bn group resisted the catalytic hydrogenation.   96 
     We initially evaluated the ability of 3 to bind to PKCδ using a synthetic PKCδ-C1B 97 
peptide (δ-C1B),30) which is a major binding site and plays a predominant role in the activation 98 
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of PKCδ by PKC ligands such as bryo-1, ATX, and TPA.  The concentration required to cause 99 
50% inhibition (IC50) of [3H]phorbol 12,13-dibutyrate (PDBu) was measured using a 100 
competitive binding assay.31,32)  Affinity for δ-C1B was expressed as a Ki value calculated from 101 
the IC50 value of 3 and the Kd value of [3H]PDBu, as reported by Sharkey and Blumberg.31)  102 
Table 1 lists the Ki value of 3 for δ−C1B along with those of aplog-1 and its 27-methyl and 103 
27-methoxy derivatives (1 and 2).  As previously reported,21,33) the stereochemistry at position 104 
27 was critical for PKC binding, and the free hydroxyl group at position 27 was indispensable.  105 
Although the amide analog 3 fulfilled these structural requirements at position 27 for PKCδ 106 
binding, the affinity of 3 (Ki = 520 nM) was approximately two orders of magnitude weaker 107 
than that of aplog-1 (Ki = 7.4 nM).  108 
     Regarding PKC activators such as 1,2-diacyl-sn-glycerol (DAG) and indolactam-V (Fig. 109 
1), the replacement of an ester group with an amide group and vice versa significantly affected 110 
their abilities to bind to PKC isozymes by changing their conformation.  The replacement of 111 
either the sn-1 or sn-2 ester group of DAG, an endogenous second messenger, with an amide 112 
group markedly reduced its ability to activate PKC isozymes.34)  The conformationally 113 
constrained analogs of DAG (DAG-lactones) with similar modifications developed by Marquez 114 
and colleagues also showed approximately ninety to two hundred-fold lower binding affinities 115 
for PKCα than those of their ester counterparts.35)  On the other hand, amide-to-ester 116 
modification in the indolactam-V analogs gave opposite results.  A lactone analog of the 117 
nine-membered indolactam-V, the core structure of teleocidins, showed a different 118 
conformational preference and was completely inactive,36) while a lactone analog of the 119 
eight-membered benzolactam-V8 took a ring conformation similar to that of benzolactam-V8 120 
with cis-amide, and exhibited twenty to ninety-fold lower affinity for PKC C1 domains than the 121 
corresponding benzolactam-V8 analog.27)  Therefore, both ester and amide analogs could bind 122 
to PKC isozymes if it adopted an appropriate conformation.   123 
     The strong binding ability of ATX to PKC isozymes was attributed to the rigid 124 
conformation of the macrocyclic ring, which included a hydrophilic pharmacophore,33) and an 125 
NMR analysis of aplog-120) indicated that its preferred macrocyclic ring conformation was 126 
similar to that of 3-deoxy-debromo-ATX (e.g., J2,3 = 10.8 and 2.8 Hz for aplog-1; 11 and 3 Hz 127 
for 3-deoxy-debromo-ATX).33)  In the case of 3, an nOe correlation between NH-26 and H-11 128 
was observed in a 2D NOESY NMR experiment in CDCl3 (Supplemental Fig. 2), suggesting 129 
that the conformation of 3 differed to those of ATX33) and aplog-1, in which the distance 130 
between these atoms could be more than 4 Å.  Since ATX and aplogs were involved in the 131 
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hydrophobic environment when bound to PKCδ-C1B in the presence of phosphatidylserine, the 132 
conformation of 3 in CDCl3 would reflect a conformation in a ternary complex of 3, PKCδ-C1B, 133 
and phosphatidylserine membrane.  In order to clarify the effects of conformational changes in 134 
3 on decreases in PKCδ binding, we performed a conformational search followed by density 135 
functional theory (DFT) calculations to estimate the relative stabilities of possible conformers.   136 
     A set of possible conformations of the macrolactone core structure of 3 was generated by 137 
the simulated annealing method, and we chose three possible conformers: the global-minimum 138 
with a trans-amide, an ATX-like conformation with a trans-amide, and a conformation with a 139 
cis-amide because the active conformation of indolactam compounds is known to be a cis-amide 140 
form.37,38)  Side chains at C-11 were attached to them and dihedral angles in the side chain 141 
were manually rotated to search for an energetically stable orientation, in which the 18-OH 142 
group is involved in intramolecular hydrogen bonding as suggested by its sharp 1H NMR signal 143 
in CDCl3.  The candidate structures were pre-optimized using the molecular mechanics method 144 
with the MMFF94s force field and the final DFT geometry optimizations were then performed 145 
at the ωB97X-D/6-31G* level of theory.39)  Figure 2 shows the resulting three possible 146 
conformers of 3 (A-C) and their relative ωB97X-D/6-31G* energies.  147 
     As described above, conformers A and B had a trans-amide bond, while C had a cis one.  148 
Conformer B resembles a stable conformation of ATX.33)  In conformers A and B, NH-26 and 149 
H-11 were spatially close (2.06 Å in A, 2.61 Å in B), which is consistent with the nOe 150 
correlation.  Furthermore, the sharp and downfield-shifted 1H NMR signal of NH-26 (7.45 151 
ppm) in CDCl3 could be explained by intramolecular hydrogen bonding between N-H and an 152 
oxygen atom in these conformers.  DFT calculations showed that conformer A had the lowest 153 
energy, and differences in energies between A-B and A-C were 1.365 and 13.259 kcal mol–1, 154 
respectively.  These results suggested that 3 existed as conformer A in CDCl3.  Since 155 
conformer B resembled but significantly diverged from the stable conformation of ATX due to 156 
the rotation of amide plane by 45º (based on N—C-1—C-2—C-3 dihedral angle), the difference 157 
in energies between conformer A and the ATX-like active conformation would be more than 158 
1.365 kcal mol–1.  Thus, a 70-fold decrease in the binding ability of 3 from aplog-1, which is 159 
equivalent to a 2.34 kcal mol–1 change in free energy, could be ascribable mainly to the change 160 
in the conformational preference. 161 
     We then evaluated the tumor-promoting activity of 3 in vitro by testing the induction of 162 
Epstein-Barr virus early antigen (EBV-EA) production.40,41)  EBV is activated by treating cells 163 
with tumor promoters such as TPA in order to produce EA, which can be detected by an indirect 164 
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immunofluorescence technique.  Aplog-1 and its C-27 derivatives (1 and 2) induced EA 165 
production more weakly than the potent tumor promoter TPA.  The ability of 3 to induce EA 166 
production was weaker than those of 1 and 2 without the ability to bind to PKC 167 
isozymes21,33) Figure 3 .  Although EA production is considered to be related to the 168 
activation of PKC isozymes,42) this result suggested that some part of the induction of EA 169 
caused by aplog-1 and its derivatives could be attributed to other mechanisms.   170 
     The anti-proliferative activity of 3 was evaluated with a panel of 39 human cancer cell 171 
lines established by Yamori and colleagues44,45)  The results for HBC-4 and NCI-H460 were 172 
shown in Figure 4 as typical examples, because aplog-1 showed stronger growth inhibitory 173 
activity against these cell lines.  Similar results were observed in MDA-MB-231, SNB-78, 174 
HCC2998, A549, LOX-IMVI, and St-4 cell lines (Supplemental Table 1).  Cell growth was 175 
estimated by the sulforhodamine B assay and expressed as a percentage of the control without 3.  176 
As expected from the weak binding affinity for PKCδ, 3 hardly inhibited their growth at low 177 
concentrations (< 10–5 M) as well as 1 and 2.  Furthermore, 3 exhibited weak cytotoxicity even 178 
at 10–4 M, whereas aplog-1, 1, and 2 induced cell death regardless of their binding affinities for 179 
PKCδthe same, 10–4 M.  This result suggests that other 180 
targets may be involved in the cytotoxicity of aplogs at 10–4 M.   181 
     In summary, we synthesized a new amide derivative of aplog-1 (3) in order to improve 182 
the stability of aplog-1 against esterases and pH changes in vivo.  Although the very weak 183 
binding of 3 to the C1B domain of PKCδ could be detected, 3 showed weak anti-proliferative 184 
activity against the 39 cancer cell lines examined, even at 10–4 M (Supplemental Table 1), and 185 
hardly induced the production of EBV-EA.  In contrast, aplog derivatives without binding 186 
affinity to PKCδ and its isozymes (1, 2)21) retained these activities at 10–4 M.  These results 187 
suggest that some of the anti-proliferative and cytotoxic activities of aplogs were attributed to 188 
unidentified targets other than PKC isozymes.  A conformational analysis and DFT 189 
calculations indicated that the stable conformation of 3 differed from that of aplog-1.  This 190 
conformational change could prevent 3 from binding to PKCδ and other target proteins 191 
responsible for anti-proliferative activity and EBV-EA induction.  Given that conformational 192 
changes in PKC ligands could affect not only biological activities, but also cellular targets, these 193 
effects must be taken into account to successfully derivatize the skeletons of aplogs in the 194 
future. 195 
     We recently developed aplog-based molecular probes and are currently attempting to 196 
identify its target proteins other than PKC isozymes.  As described above, 27-methyl and 197 
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27-methoxy derivatives (1, 2) did not exhibit the ability to bind to PKC isozymes, but had 198 
marked anti-proliferative and cytotoxic activities at 10-4 M, indicating that 1 and 2 were not 199 
suitable as inactive controls for the target analysis.  Since 3 exhibited weak binding affinity for 200 
PKC, but little cytotoxic activity even at 10-4 M, it would be suitable as an inactive control for 201 





     The following spectroscopic and analytical instruments were used: digital polarimeter, 207 
DIP-1000 (Jasco, Tokyo, Japan); 1H and 13C NMR, Avance III 400, Avance III 500, and Avance 208 
II 800 (reference TMS, Bruker, Germany); HPLC, model 600E with a model 2487 UV detector 209 
(Waters, Tokyo, Japan); and HR-FAB-MS, JMS-600H (JEOL, Tokyo, Japan) and JMS-700 210 
(JEOL, Tokyo, Japan).  HPLC was carried out on a YMC-packed ODS-A AA12S05-2510WT 211 
(Yamamura Chemical Laboratory, Kyoto, Japan).  Wakogel® C-200 (silica gel, Wako Pure 212 
Chemical Laboratory, Osaka, Japan) was used for column chromatography.  [3H]PDBu (18.7 213 
Ci/mmol) was custom-synthesized by Perkin-Elmer Life Sciences Research Products (Boston, 214 
MA).  The PKCδ C1B peptide was synthesized as reported previously.30)  All other chemicals 215 
and reagents were purchased from chemical companies and used without further purification.   216 
 217 
Synthesis of 3.  Compound 4 was prepared as reported previously.28)  [α]D +13.2º (c = 0.44, 218 
MeOH, 10.9 ºC).  TFA (0.9 mL) was added to a solution of 4 (35.8 mg, 89.7 µmol) in 219 
dichloromethane (0.9 mL) at 0 ºC.  After 4 h of stirring at room temperature, the reaction 220 
mixture was concentrated in vacuo to afford 5 (29.3 mg, 85.4 µmol, 95%) as a clear oil.  1H 221 
NMR (500 MHz, CDCl3, 0.015 M) ppm: δ 2.70 (2H, d, J = 5.9 Hz), 3.55-3.59 (2H, m), 4.23 222 
(1H, br. s), 4.50 (2H, s), 5.09 (2H, s), 5.41 (1H, br. d, J = 8.1 Hz), 7.27-7.37 (10H, m); 13C NMR 223 
(125 MHz, CDCl3, 0.015 M) ppm: δ 35.8, 47.8, 66.9, 70.8, 73.4, 127.7 (2C), 127.9 (2C), 128.1, 224 
128.2, 128.5 (2C), 128.6 (2C), 136.4, 137.7, 155.9, 174.1; HR-EI-MS m/z: 343.1427 ([M]+ 225 
Calcd. for C19H21NO5 343.1420) [α]D +16.1º (c = 0.15, CHCl3, 10.3 ºC). 226 
     2,4,6-trichlorobenzoyl chloride (28.0 µL, 179 µmol, 1.7 equiv.) was added to a solution of 227 
5 (51.1 mg, 149 µmol, 1.4 equiv.) and Et3N (24.9 µL, 179 µmol, 1.7 equiv.) in toluene (1.1 mL) 228 
at room temperature.  After 3 h of stirring at room temperature, the supernatant of the 229 
suspension was added to a solution of 620) (50.0 mg, 105 µmol) and DMAP (27.0 mg, 221 µmol, 230 
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2.1 equiv.) in toluene (1.1 mL) at room temperature.  The mixture was stirred at 50 ºC for 2 h 231 
and then poured into H2O (5.0 mL).  The mixture was extracted with EtOAc (5 mL x 3).  The 232 
combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated 233 
in vacuo.  The residue was purified by column chromatography (silica gel, 10% → 20% 234 
EtOAc/hexane) to afford 7 (67.8 mg, 84.4 µmol, 80%) as a clear oil.  1H NMR (500 MHz, 235 
CDCl3, 0.0027 M) ppm: δ 0.86 (3H, s), 0.95 (3H, s), 1.33-1.49 (9H, m), 1.57-1.66 (4H, m), 2.19 236 
(1H, br. d, J = 15.5 Hz), 2.26 (1H, m), 2.35 (1H, m), 2.57 (2H, t, J = 7.8 Hz), 2.61 (1H, dd, J = 237 
15.8, 8.0 Hz), 2.69 (1H, dd, J = 5.8 Hz), 3.49-3.60 (4H, m), 4.16-4.21 (2H, m), 4.47-4.52 (2H, 238 
m), 4.95-5.02 (2H, m), 5.04 (2H, s), 5.06-5.09 (3H, m), 5.56 (1H, br. d, J = 8.8 Hz), 5.80 (1H, 239 
m), 6.78-6.82 (3H, m), 7.18 (1H, t, J = 7.8 Hz), 7.27-7.45 (14H, m) ; 13C NMR (125 MHz, 240 
CDCl3, 0.0027 M) ppm: δ 22.0, 24.8, 25.3, 26.1, 27.2, 31.3, 33.7, 34.5, 35.6, 36.0, 36.5, 36.8, 241 
40.9, 48.0, 63.9, 66.7, 68.4, 70.0, 71.1, 71.7, 73.3, 100.1, 111.8, 115.2, 116.6, 121.2, 127.5 (2C), 242 
127.6 (2C), 127.8, 127.9 (2C), 128.1, 128.1, 128.4 (2C), 128.5 (2C), 128.6 (2C), 129.2, 135.4, 243 
136.6, 137.3, 137.9, 144.6, 155.8, 158.9, 171.3; HR-FAB-MS (matrix, m-nitrobenzyl alcohol) 244 
m/z: 826.4324 ([M+Na]+ Calcd. for C50H61NO8Na 826.4295) [α]D +19.7º (c = 0.14, CHCl3, 28.9 245 
ºC). 246 
     KMnO4 (13.1 mg, 83.2 µmol, 1 equiv.) was added to a suspension of NaIO4 (143 mg, 247 
0.666 mmol, 8 equiv.) in pH 7.2 phosphate buffer (6.9 mL) in one portion.  After 5 min of 248 
stirring at room temperature under an Ar atmosphere, the mixture was added to a solution of 7 249 
(66.8 mg, 83.2 µmol) in t-BuOH (6.9 mL).  The reaction mixture was stirred at room 250 
temperature for 1 h, and the reaction was quenched with Na2S2O3 (39.5 mg).  The organic layer 251 
was separated, and the aqueous layer was extracted with EtOAc (20 mL x 3).  The combined 252 
organic layer were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo.  253 
The residue was purified by column chromatography (silica gel, 20% EtOAc/hexane containing 254 
1% AcOH) to afford a carboxylic acid (50.8 mg, 61.9 µmol, 74%) as a clear oil.   255 
     N,N’-dicyclohexylcarbodiimide (7.3 mg, 35.4 µmol, 1.5 equiv.) in MeCN (0.20 mL) was 256 
added to a solution of the carboxylic acid (19.4 mg, 23.6 µmol) and N-hydroxysuccinimide (5.4 257 
mg, 47.2 µmol, 2 equiv.) in MeCN (0.20 mL) at 0 ºC.  The reaction mixture was stirred at 0 ºC 258 
for 10 h, then concentrated in vacuo.  The residue was purified by column chromatography 259 
(silica gel, 5% → 10% → 20% → 30 % EtOAc/hexane) to afford a crude activated ester 260 
(28.1 mg).  A solution of the activated ester (26.7 mg) in MeOH (1.0 mL) was added to 20% 261 
Pd(OH)2-C (wet support, Aldrich) (7.8 mg) in a flask at room temperature.  The mixture was 262 
vigorously stirred under a H2 atmosphere at room temperature for 4.5 h.  The mixture was 263 
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filtered and the filtrate was concentrated in vacuo.  The residue was dissolved in MeOH (0.6 264 
mL), and again added to 20% Pd(OH)2-C (wet support, Aldrich) (5.9 mg) in a flask at room 265 
temperature.  The mixture was vigorously stirred under a H2 atmosphere at room temperature 266 
for 2.5 h.  The mixture was filtered and the filtrate was concentrated in vacuo.  This 267 
procedure was repeated two times and a total of 38.5 mg (46.9 µmol) of the carboxylic acid was 268 
reacted.  These residues were purified by HPLC (column, YMC-Pack ODS-A 269 
AA12S05-2510WT; solvent MeOH/H2O = 75:25, flow rate 3.0 mL/min; pressure, 2100 psi; UV 270 
detector 254 nm; retention time, 20.1 min) to afford 3 (5.2 mg, 10.6 µmol, 23%) as a clear oil.  271 
1H NMR (400 MHz, CDCl3, 0.0036 M) ppm: δ 0.96 (3H, s, H3-23), 1.00 (3H, s, H3-22), 272 
1.38-1.59 (9H, m, H2-4, H2-5, H-10a, H2-12, H2-13), 1.64 (2H, m, H2-14), 1.71 (1H, dd, J = 15.5, 273 
3.7 Hz, H-8α), 1.79 (1H, m, H-10b), 2.28 (1H, dd, J = 15.1, 1.1 Hz, H-2a), 2.46 (1H, m, H-8β), 274 
2.55-2.65 (4H, m, H-2b, H2-15, H-25a), 2.95 (1H, dd, J = 16.5, 10.7 Hz, H-25b), 3.70-3.87 (4H, 275 
m, H-3, H-26, H2-27), 4.09 (1H, m, H-11), 4.45 (1H, dd, J = 7.6, 5.0 Hz, OH), 5.21 (1H, m, 276 
H-9), 6.27 (1H, s, Ph-OH), 6.65-6.74 (3H, m, H-17, H-19, H-21), 7.13 (1H, t, J = 7.8 Hz, H-20), 277 
7.45 (1H, br. d, J = 4.7 Hz, NH); 13C NMR (125 MHz, CDCl3, 0.0029 M) ppm: δ 21.5 (C-22), 278 
24.2 (C-13), 25.6 (C-8), 25.9 (C-23), 27.8 (C-4), 30.2 (C-14), 34.2 (C-5 or 10 or 12), 34.4 (C-5 279 
or 10 or 12), 34.7 (C-5 or 10 or 12), 35.3 (C-15), 36.3 (C-25), 37.3 (C-6), 43.8 (C-2), 51.6 280 
(C-26), 63.9 (C-11), 64.5 (C-27), 68.5 (C-9), 71.3 (C-3), 101.3 (C-7), 112.8 (C-19), 115.1 281 
(C-17), 120.6 (C-21), 129.4 (C-20), 144.4 (C-16), 156.3 (C-18), 170.3 (C-24), 173.4 (C-1); 282 
HR-FAB-MS (matrix, m-nitrobenzyl alcohol) m/z: 490.2812 ([M+H]+ Calcd. for C27H40NO7 283 
490.2805) [α]D +38.9º (c = 0.074, CHCl3, 9.6 ºC). 284 
 285 
Inhibition of specific binding of [3H]PDBu to the PKCδ-C1B peptide.  The binding of 286 
[3H]PDBu to the δ-C1B peptide was evaluated by the procedure of Sharkey and Blumberg31) 287 
with modifications as reported previously32) using 50 mM Tris-maleate buffer (pH 7.4 at 4 ºC), 288 
13.8 nM δ-C1B peptide, 20 nM [3H]PDBu (18.7 Ci/mmol), 50 µg/mL 289 
1,2-dioleoyl-sn-glycero-3-phospho-L-serine sodium salt (Sigma), 3 mg/mL bovine γ-globulin, 290 
and various concentrations of an inhibitor.  Binding affinity was evaluated based on the 291 
concentration required to inhibit the specific binding of [3H]PDBu by 50%, the IC50, which was 292 
calculated by a computer program with a probit procedure.46)  The inhibition constant, Ki, was 293 
calculated by the method of Sharkey and Blumberg.31)  294 
 295 
EBV-EA induction test.  Human B-lymphoblastoid Raji cells (5 × 105/mL) were incubated at 296 
  10 
37 °C under a 5% CO2 atmosphere in 1 mL of RPMI 1640 medium (supplemented with 10% 297 
fetal bovine serum) with 4 mM sodium n-butyrate (a synergist) and 10, 100, or 1000 nM of each 298 
test compound.  Each test compound was added as 2 µL of a DMSO solution (5, 50, and 500 299 
µM stock solution) along with 2 µL of DMSO; the final DMSO concentration was 0.4%.  300 
After 48 h of incubation, smears were made from the cell suspension, and the 301 
EBV-EA-expressing cells were stained by a conventional indirect immunofluorescence 302 
technique with the serum of an NPC patient’s (a gift from Kobe University, Japan) and 303 
FITC-labeled anti-human IgG (DAKO, Glostrup, Denmark) as reported previously.41)  At least 304 
500 cells were counted in each assay and the proportion of EA-positive cells was recorded.  305 
Cell viability exceeded 60% in all experiments. 306 
 307 
Measurements of cell growth inhibition.  A panel of 39 human cancer cell lines established by 308 
Yamori and colleagues44) according to the NCI method with modifications was employed, and 309 
cell growth inhibitory activity was measured as reported previously.45)  In brief, cells were 310 
plated on 96-well plates in RPMI 1640 medium supplemented with 5% fetal bovine serum and 311 
allowed to attach overnight.  The cells were incubated with each test compound for 48 h.  312 
Cell growth was estimated by the sulforhodamine B assay.  Absorbance for the control well 313 
(C) and test well (T) was measured at 525 nm along with that for the test well at time 0 (T0).  314 
Cell growth inhibition (% growth) by each concentration of the drug (10–8, 10–7, 10–6, 10–5, and 315 
10–4 M) was calculated as 100[(T − T0)/ (C − T0)] using the average of duplicate points. 316 
 317 
Conformational search of 3.  The generation of a conformer library of 3 by a simulated 318 
annealing method under a vacuum was performed using the GROMACS program47) (version 319 
4.6.5) with a general AMBER force field (GAFF).48)  The side chain at C11 of 3 was replaced 320 
with a methyl group.  All bonds were constrained using the LINCS algorithm.  The annealing 321 
temperature was initially set to 1,500 K in order to surpass the cis-trans isomerization barrier in 322 
this system and the temperature was kept constant for 1 ps.  The temperature was linearly 323 
dropped to 100 K over 1 ps and then to 0 K over 1 ps, and kept at the same temperature for 1 ps.  324 
This 5-ps cycle was repeated 200 times to give the conformer library. 325 
     Three possible conformers were selected from this library: the global-minimum with 326 
trans-amide, ATX-like conformation with trans-amide, and a conformation with cis-amide.  327 
The side chains at C-11 were attached to them and dihedral angles in the side chain were 328 
manually rotated to search for energetically stable orientation.  The candidate structures were 329 
  11 
pre-optimized using the molecular mechanics method with the MMFF94s force field as 330 
implemented in Avogadro49) (version 1.1.1) and then optimized using the DFT method at the 331 
level of ωB97X-D/6-31G*39) employing Gaussian09.50)  The obtained geometries were 332 
characterized as minimum structures on the basis of their harmonic vibrational frequencies and 333 
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Table 1.  Ki values for the inhibition of [3H]PDBu-binding by aplog-1, 1, 2, and 3. 509 
 Ki (nM) 
 Aplog-1a 1b 2b 3 
δ−C1B peptide 7.4 > 2,500 > 2,500 520 (19)c 
a Cited from ref. 20.  b Cited from ref. 21. 510 
cValues in parentheses represent the standard deviation from triplicate experiments.  511 
18 
Figure captions 512 
513 
Fig. 1.  Structures of bryostatin-1, aplysiatoxin, its simplified analogs (1-3), teleocidin-B4, 514 
indolactam-V, and its 8-membered analogs. 515 
 516 
Fig. 2.  Cross-eyed stereo views of possible conformations of 3 (A–C) and their relative 517 
energies at the ωB97X-D/6-31G* level.  Dashed lines represent hydrogen bonding.  518 
 519 
Fig. 3.  EBV-EA production induced by TPA, aplog-1, 1, 2, and 3. 520 
The percentages of EA-positive cells are shown.  Sodium n-butyrate (4 mM) was added to all 521 
samples to enhance the sensitivity of Raji cells.  Only 0.1% of cells were positive for EA at 4 522 
mM sodium n-butyrate.  The final concentration of DMSO was 0.4%.  Cell viability 523 
exceeded 60%.  Error bars show the standard error of the mean (n = 3).  aCited from ref. 43. 524 
bCited from ref. 21. 525 
 526 
Fig. 4.  Effects of aplog-1, 1, 2, and 3 on the growth of human cancer cell lines: HBC-4 527 
(breast) and NCI-H460 (non-small cell lung). 528 
Cell growth was expressed as a percentage of the control (media only).  The results were 529 
presented as the average of duplicate points. 530 
 531 
Scheme 1.  (a) TFA, dichloromethane (95%); (b) 5, 2,4,6-trichlorobenzoyl chloride, Et3N, 532 
DMAP, toluene (80%); (c) KMnO4, NaIO4, t-BuOH, pH 7 buffer (74%); (d) 533 
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Supplemental Fig. 1.   1H-1D NMR spectrum of amide-aplog-1 (3) 















Supplemental Fig. 2.   2D 1H-1H NOESY spectrum of amide-aplog-1 (3) 

















Supplemental Table 1.  Growth inhibition assay against human cancer cell lines.     
 
 
cancer cell line 
log GI50 (M)  Cell growth at 10−4 M (% of control) 
Aplog-1a 3  Aplog-1 1 2 3 
breast HBC-4 –6.33 –4.46  –88 –83 –71 21 
 BSY-1 –4.87 –4.37  –94 –93 –88 27 
 HBC-5 –4.76 –4.20  –85 –84 –92 40 
 MCF-7 –4.72 –4.50  –82 –72 –80 8 
 MDA-MB-231 –5.61 –4.64  –92 –87 –95 9 
CNS U251 –4.83 –4.47  –89 –93 –81 8 
 SF-268 –4.83 –4.31  –83 –87 –72 31 
 SF-295 –5.06 –4.54  –80 –61 –67 4 
 SF-539 –4.97 –4.37  –84 –75 –81 16 
 SNB-75 –4.80 –4.39  –84 –81 –70 17 
 SNB-78 –4.72 –4.23  –88 –91 –55 38 
colon HCC2998 –5.43 –4.32  –86 –84 –78 22 
 KM-12 –4.86 –4.35  –87 –67 –71 24 
 HT-29 –4.77 –4.53  –86 –80 –79 –8 
 HCT-15 –4.76 –4.31  –75 –67 –46 28 
 HCT-116 –4.79 –4.40  –87 –81 –98 16 
lung NCI-H23 –4.88 –4.26  –75 –68 –71 25 
 NCI-H226 –4.81 –4.49  –79 –78 –89 9 
 NCI-H522 –4.87 –4.65  –88 –87 –89 –25 
 NCI-H460 –5.60 –4.50  –78 –81 –59 9 
 A549 –5.32 –4.49  –79 –76 –75 9 
 DMS273 –4.90 –4.38  –80 –74 –84 16 
 DMS114 –4.79 –4.53  –84 –83 –85 3 
melanoma LOX-IMVI –5.74 –4.73  –83 –70 –91 –62 
ovarian OVCAR-3 –4.78 –4.48  –84 –85 –78 10 
 OVCAR-4 –4.75 –4.35  –85 –87 –94 32 
 OVCAR-5 –4.95 –4.00  –93 –87 –96 64 
 OVCAR-8 –4.71 –4.35  –73 –62 –80 23 
 SK-OV-3 –4.69 –4.22  –96 –67 –40 35 
renal RXF-631L –4.79 –4.29  –91 –88 –77 29 
 ACHN –4.92 –4.46  –92 –97 –28 8 
stomach St-4 –5.55 –4.39  –84 –72 –72 21 
 MKN1 –4.86 –4.26  –81 –76 –90 31 
 MKN7 –4.78 –4.44  –87 –59 –60 13 
 MKN28 –4.74 –4.43  –63 –62 –71 19 
 MKN45 –5.33 –4.31  –89 –61 –43 31 
 MKN74 –4.76 –4.43  –79 –69 –78 16 
prostate DU-145 –4.85 –4.29  –86 –68 –62 31 
 PC-3 –4.96 –4.41  –65 –69 –56 21 
MG-MIDb –4.98 –4.40      
a Nakagawa, Y.; Yanagita, R. C.; Hamada, N.; Murakami, A.; Takahashi, H.; Saito, N.; Nagai, 
H.; Irie, K. J. Am. Chem. Soc. 2009, 131, 7573-7579. 
b Full panel mean-graph midpoint. 
 
